Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study

The SARS-CoV-2 pandemic led to the development of various vaccines. The BNT162b2 mRNA vaccine was the first approved due to its efficacy in eliciting a humoral immunity response after the second dose. However, a decrease in the antibody concentration was observed over time. Therefore, the administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Panico, Alessandra, Lobreglio, Giambattista, Bagordo, Francesco, Zizza, Antonella, De Donno, Antonella, Rosato, Chiara, Lazzari, Roberta, Chicone, Michele, Indino, Floriano, Recchia, Virginia, Alifano, Pietro, Grassi, Tiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229040/
https://www.ncbi.nlm.nih.gov/pubmed/35746470
http://dx.doi.org/10.3390/vaccines10060862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229040/
https://www.ncbi.nlm.nih.gov/pubmed/35746470
http://dx.doi.org/10.3390/vaccines10060862

Ejemplares similares